Novartis Kisqali demonstrates nearly five years median overall survival in metastatic breast cancer
Novartis announced updated median overall survival (OS) results for Kisqali (ribociclib) in combination with endocrine therapy, marking the longest survival data ever reported in…
Read More...
Read More...
